Pfizer and BioNTech Reports P-II/III Trial Results of Omicron BA.4/BA.5-Adapted Bivalent Booster for COVID-19
- The P-II/III trial to evaluate Omicron BA.4/BA.5-Adapted Bivalent Booster (30µg) in 900 healthy volunteers aged ≥12yrs.
- The results showed ~4-fold higher neutralizing Ab titers against Omicron BA.4/BA.5 sublineages over original COVID-19 vaccine in individuals aged ≥55yrs., increased 13.2-fold from pre-booster levels in adults aged ≥55yrs. & 9.5-fold in adults aged 18-55yrs. over 2.9-fold increase who received the original booster vaccine & higher immune was observed. The safety & tolerability profile remains favorable & similar to the original COVID-19 vaccine
- The companies will share the results with the EMA & other global health authorities shortly. The US FDA has authorized a booster dose for use in patients aged ≥5yrs. in emergencies
Ref: Globenewswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected]